Cardiometabolic Disease in Patients with HIV: Who's at Greatest Risk?

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Cardiometabolic Risk in HIV Treatment: Balancing ART Choice and Potential for Weight Gain

Cardiometabolic Disease in Patients with HIV: Who's at Greatest Risk?

ReachMD Healthcare Image
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
  • Overview

    This series of bite-sized episodes will provide information about the cardiometabolic risk and potential for weight gain faced by patients with HIV. Tune in to hear Drs. Sorana Segal-Maurer, David Wohl, and Carl Fichtenbaum discuss the guidelines, strategies, data, and adverse events you need to be aware of to provide the best care for your patients.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Sorana Segal-Maurer, MD
    Director, The Dr. James J. Rahal Jr. Division of Infectious Diseases
    NewYork-Presbyterian Queens
    Professor of Clinical Medicine
    Weill Cornell Medical College, Cornell University
    New York, NY

    Research: Gilead
    Consulting Fees: Gilead, Janssen, ViiV Healthcare

    Carl J. Fichtenbaum, MD
    Gregory W. Rouan Professor of Internal Medicine
    University of Cincinnati
    Cincinnati, OH

    Research: Gilead Sciences, Merck & Co., Inc., ViiV Healthcare
    Consulting Fees: Theratechnologies, ViiV Healthcare

    David Wohl, MD
    Professor of Medicine
    The University of North Carolina at Chapel Hill
    Chapel Hill, NC

    Research: Gilead, Merck & Co., Inc., ViiV Healthcare
    Consulting Fees: Gilead, Janssen, Theratechnologies, ViiV Healthcare

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Keith Johnson has nothing to disclose.
    • Andrea Mathis has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Susan Smith, MN, PhD has ownership interest in Hepion Pharmaceuticals. 
    • Rosanne Strauss, PharmD, MBA, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Assess cardiometabolic risk factors in patients with HIV receiving antiretroviral therapy (ART) at regular intervals
    • Select antiretroviral (ARV) regimens to help protect cardiometabolic health in patients with HIV at known increased risk
    • Identify benefits of some non-nucleoside reverse transcriptase inhibitors (NNRTIs) when there is a need to avoid or switch from integrase strand transfer inhibitor (INSTI)-based ARV regimens
  • Target Audience

    This activity is designed to meet the educational needs of infectious disease physicians, primary care physicians, and infectious disease nurses and physician assistants.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 8/21/2024. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Merck & Co., Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule14 Jul 2024